Parkinson's disease - A multifactorial neurodegenerative disorder

Journal of Neural Transmission, Supplement

Volumn , Issue 56, 1999, Pages 113-125

  Riess, Olaf ^a   Kruger R ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; CONFERENCE PAPER; DEGENERATIVE DISEASE; DISEASE CLASSIFICATION; DNA POLYMORPHISM; HUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; GENETICS; METABOLISM; PATHOLOGY; REVIEW;

HUMANS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 0032588330     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6360-3_6     Document Type: Conference Paper

References (42)

1. Balk J-H, Picetti R, Salardi A, Thiriet G, Dierich A, Depauis A, Le Meur M, Borrelli E (1995) Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377: 424-428
2. Bandmann O, Vaughan J, Holmans P, Marsden CD, Wood NW (1997) Association of slow acctylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 350: 1136-1139
3. 18F-Dopa and positron emission tomography. Neurology 42: 1894-1900
4. Chinaglia G, Probst A, Palacios JM (1990) Neurotensin receptors in Parkinson's disease and progressive supranuclear palsy: an autoradiografic study in basal ganglia. Neuroscicnce 39(2): 351-360
5. Costa P, Chekoway H, Levy D, Smith-Weller T, Franklin GM, Swanson PD, Costa LG (1997) Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease. Am J Med Gen 74: 154-156
6. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O (1994) Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 91: 5104-5108
7. Casser T, Wszolek ZK, Trofatter J, Ozelius L, Uitti RJ, Lee CS, Gusella J, Pfeiffer RF, Calne DB, Breakfield XO (1994) Genetic linkage studies in autosomal dominant Parkinsonism: evaluation of seven candidate genes. Ann Neurol 36: 387-396
8. Gasser T, Müller-Myhsok B, Wszolek ZK, et al (1997) Genetic complexity and Parkinson's disease. Science 277: 388-389
9. Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC (1990) A large kindred with adPD. Ann Neurol 27: 276-282
10. Golbe LI (1993) A large kindred with PD: onset age, segregation ratios, and anticipation. Mov Disord 8: 406
11. Harrington KA, Augood SJ, Kingsbury AE, Foster OJ, Emson PC (1996) Dopamine transporter (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease. Mol Brain Res 36(1): 157-162
12. Heikkila RE, Kindt MV, Sonsalla PK (1988) Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-l 1,2,5,6-tetrahydropyridine. Proc Natl Acad Sci USA 85: 6172-6176
13. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184
14. Hughes AJ, Daniel SE, Blankson S, Lees AJ (1993) A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 50: 140-148
15. Hyman C, Hofer M, Barde YA (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350: 230-232
16. Javoy-Agid G, Hirsch EC, Dumas S (1990) Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the subslantioa nigra in Parkinson's disease: an in situ hybridization study. Neuroscience 38: 245-253
17. Jellinger KA (1993) Pathogenese und Pathophysiologie der Parkinson-Krankheit. Neuropsychiatrie 7(1): 29-37
18. Jenner P, Schapira AHV, Marsden CD (1992) New insights into the cause of Parkinson's disease. Neurology 42: 2241-2250
19. Kimpara T, Takeda A, Watanabe K, Itoyama Y, Ikawa S, Watanabe M, Arai H, Sasaki H, Higuchi S, Okita N, Takase S, Saito H, Takahashi K, Shibahara S (1997) Microsatellite polymorphism in the human heme oxygenase-1 promoter and its application in association studies with Alzheimer and Parkinson disease. Hum Genet 100: 145-147
20. Kish SJ, Rajput A, Gilbert J, Rozdilsky B, Chang LJ, Shannak K, Hornykiewicz O (1986) Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss. Ann Neurol 20(1): 26-31
21. Kitayama S, Wang J-B, Uhl GR (1993) Deopamine transporter mutants selectively increase MPP+ transport. Synapse 15: 58-62
22. Krüger R, Kuhn W, Müller Th, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 18: 106-108
23. Kurth JH, Kurth MC, Poduloso SE, Schwankhaus JD (1993) Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 33: 368-372
24. Kurth JH, Eggers-Sedlet B, Liebermann A, Kurth MC (1997) Mov Disord 12(5): 835
25. Langston JW, Irwin I, Langston EB, Forno LS (1984) Pargyline prevents MPTP induced parkinsonism in primates. Science 225: 1480-1482
26. LeCouteur DG, Leighton PW, McCann SJ, Pond SM (1997) Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. Mov Disord 12: 760-763
27. Nishino N, Fujiwara H, Nogushi-Kuno SA, Tanaka C (1988) GABAA receptor but not muscarinic receptor density was decreased in the brain of patients with Parkinson's disease. Jpn J Pharmacol 48(3): 331-339
28. Planté-Bordeneuve V, Davis MB, Maraganore DM, Marsden CD, Harding AE (1994) Tyrosine hydroxylase polymorphism in familial an sporadic Parkinson's disease. Mov Disord 9: 337-339
29. Planté-Bordeneuve V, Taussig B, Thomas F, Said G, Wood NW, Marsden CD, Harding AE (1997) Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease. Neurology 48: 1589-1593
30. Polymeropoulos M, Lavedan C, Leroy E, et al (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047
31. Riederer P, Konradi C, Hebenstreit G, Youdim MB (1989) Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol Scand [Suppl] 126: 41-45
32. Schellenberg GD (1995) Genetic dissection of Alzheimer disease, a heterogeneous disorder. Proc Natl Acad Sci USA 92: 8552-8559
33. Schmidt ML, Martin JA, Lee VMY, Trojanowski JQ (1996) Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Acta Neuropathol 91: 475-481
34. Scott WK, Stajich JM, Yamaoka LH, Speer MC, Vance JM, Roses AD, Pericak-Vance MA, The Deane Laboratory Parkinson Disease Research Group (1997) Genetic complexity and Parkinson's disease. Science 277: 387-388
35. Seeman P, Van Tol HMM (1994) Dopamine receptor pharmacology. TIPS 15: 264-270
36. Seidler A, Hellenbrand W, Robra B-P, Vieregge P, Nischan P, Joerg J, Oertel WH, Ulm G, Schneider E (1996) Possible environmental, occupational and other ecological factors for Parkinson's disease: a case control study in Germany. Neurology 46: 1275-1284
37. Spillantini MG, Schmidt ML, Lee VM-Y, Jakes R, Goedert M (1997) α-Synucelin in Lewy bodies. Nature 388: 839-840
38. Tipton KG, Singer TP (1993) Advances in our understanding of the mechanisms of neurotoxicity of MPTP and related compounds. J Neurochem 61: 1191-1206
39. Uèda K, et al (1993) Proc Natl Acad Sci USA 90: 11282-11286
40. Uitti RJ, Calne DB (1993) Palhogenesis of idiopathic parkinsonism. Eur Neurol 33: 6-23
41. Yamada M, Yamada M, Richelson E (1995) Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain. Neuroscience 64(2): 405-417
42. Zareparsi S, Kaye J, Camicioli R, Grimslid H, Oken B, Litt M, Nutt J, Bird T, Schellenberg G, Payami H (1997) Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes. Ann Neurol 42: 655-658